MedWatch

Welcome news for Novo as diabetes combo wins US approval

Novo Nordisk said in the wee hours of the morning that it has finally won approval of its combination treatment of diabetes, Xultophy, in the US.

Mads Krogsgaard Thomsen, chief science officer, Novo Nordisk

Monday shortly before midnight local time, Danish pharma group Novo Nordisk added to its portfolio of approved diabetes drugs on the crucial and fiercely competitive US market.

The company said in a press release it had won an important approval of its diabetes medicine Xultophy, which combines its basal insulin Tresiba (insulin degludec) and its GLP-1 analogue Victoza (liraglutide).

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier